Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies

被引:19
|
作者
Brezinski, Elizabeth A. [1 ]
Armstrong, April W. [2 ]
机构
[1] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA
[2] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO 80045 USA
关键词
ANTITUMOR NECROSIS FACTOR; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ULTRAVIOLET-B PHOTOTHERAPY; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; NATIONAL PSORIASIS; PATIENT PREFERENCES; MEDICAL BOARD; PHASE-III; ETANERCEPT;
D O I
10.12788/j.sder.0086
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Achieving treatment success among patients with moderate to severe psoriasis is a clinically relevant and important issue facing clinicians and patients. Despite advances in systemic therapy, most patients with moderate to severe psoriasis are not satisfied with their treatment. We will discuss strategies to maximize treatment success through the establishment of treatment goals and tailoring of biologic therapy for patients with difficult-to-treat psoriasis. Specifically, we provide evidence-based highlights on the development of biologics, recommendations by psoriasis expert groups on treatment goals, approaches to achieve treatment to defined targets, and therapeutic strategies to customize biologic treatment for nonresponders. The discussion on nonresponders focuses on subpopulations of interest including patients with significant obesity antidrug antibody formation, personal preferences for medication administration, and treatment nonadherence. We also highlight circumstances where the selection of the systemic medication is driven by safety considerations. As expectation for efficacy and safety increases with continued biologic development for psoriasis, devising real-world treatment strategies to maximize treatment success is critical to improve the overall physical and psychosocial wellbeing of psoriasis patients. (C) 2014 Frontline Medical Communications
引用
收藏
页码:91 / 97
页数:7
相关论文
共 50 条
  • [41] Biologic Agents for Moderate-to-Severe Plaque Psoriasis Mechanisms of Action and Treatment Considerations
    Cantrell, Wendy
    Kaler, Rhonda
    [J]. JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2014, 6 (05) : S12 - S30
  • [42] Apremilast in combination with systemic and biologic therapies for psoriasis treatment
    Ighani, Arvin
    Georgakopoulos, Jorge R.
    Walsh, Scott
    Shear, Neil H.
    Yeung, Jensen
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB46 - AB46
  • [43] Tuberculosis testing and the use of biologic therapies for the treatment of psoriasis
    Menter, MA
    Cather, JC
    Abromovits, W
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P176 - P176
  • [44] Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document
    Belinchon Romero, Isabel
    Dauden, Esteban
    Ferrandiz Foraster, Carlos
    Gonzalez-Cantero, Alvaro
    Carrascosa Carrillo, Jose Manuel
    [J]. ANNALS OF MEDICINE, 2021, 53 (01) : 1727 - 1736
  • [45] Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis
    Zhang, Mingliang
    Brenneman, Susan K.
    Carter, Chureen T.
    Essoi, Breanna L.
    Farahi, Kamyar
    Johnson, Michael P.
    Lee, Seina
    Olson, William H.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 777 - 784
  • [46] The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
    Nyholm, Nanna
    Dansa, Anne
    Schnack, Henrik
    Colombo, Giorgio Lorenzo
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 607 - 619
  • [47] Low treatment satisfactions among moderate to severe psoriasis patients treated with conventional therapies
    Ding, Q.
    Fan, T.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 40 - 41
  • [48] ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS: ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB
    Webber, J. M.
    Lloyd, A. C.
    Lebmeier, M.
    Conway, P.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A456 - A456
  • [49] Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
    Akshitha Thatiparthi
    Amylee Martin
    Jeffrey Liu
    Alexander Egeberg
    Jashin J. Wu
    [J]. American Journal of Clinical Dermatology, 2021, 22 : 425 - 442
  • [50] Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
    Thatiparthi, Akshitha
    Martin, Amylee
    Liu, Jeffrey
    Egeberg, Alexander
    Wu, Jashin J.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (04) : 425 - 442